CN114366764A - 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物 - Google Patents
一种提高人体免疫力，预防和/或治疗骨关节炎的组合物 Download PDFInfo
- Publication number
- CN114366764A CN114366764A CN202011101697.3A CN202011101697A CN114366764A CN 114366764 A CN114366764 A CN 114366764A CN 202011101697 A CN202011101697 A CN 202011101697A CN 114366764 A CN114366764 A CN 114366764A
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- group
- curcumin
- osteoarthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000036039 immunity Effects 0.000 title description 10
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 30
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical class OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000004148 curcumin Substances 0.000 claims abstract description 15
- 235000012754 curcumin Nutrition 0.000 claims abstract description 15
- 229940109262 curcumin Drugs 0.000 claims abstract description 15
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 15
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 13
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 13
- 239000001168 astaxanthin Substances 0.000 claims abstract description 13
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 13
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 13
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 4
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 3
- 239000004863 Frankincense Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 18
- 240000007551 Boswellia serrata Species 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 235000018062 Boswellia Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 2
- 229920001531 copovidone Polymers 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- 229920000175 Pistacia lentiscus Polymers 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 abstract description 9
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 abstract description 9
- 206010003246 arthritis Diseases 0.000 abstract description 7
- 239000005445 natural material Substances 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 208000018937 joint inflammation Diseases 0.000 abstract description 2
- 241000717739 Boswellia sacra Species 0.000 abstract 1
- 208000008558 Osteophyte Diseases 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 201000010934 exostosis Diseases 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000000845 cartilage Anatomy 0.000 description 7
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 7
- 229960000590 celecoxib Drugs 0.000 description 7
- 210000000629 knee joint Anatomy 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000001188 articular cartilage Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 108010001517 Galectin 3 Proteins 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 244000163122 Curcuma domestica Species 0.000 description 4
- 235000003392 Curcuma domestica Nutrition 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 235000003373 curcuma longa Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 210000005065 subchondral bone plate Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 201000004595 synovitis Diseases 0.000 description 4
- 235000013976 turmeric Nutrition 0.000 description 4
- 102000000802 Galectin 3 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100039558 Galectin-3 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229940124600 folk medicine Drugs 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000013521 mastic Substances 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- 230000003349 osteoarthritic effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
- 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 231100000783 metal toxicity Toxicity 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000004353 tibial menisci Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种组合物，其包含具有以下重量份的组分：改性柑橘果胶(MCP)：5‑150份，乳香(乳香酸)：5‑100份，虾青素：1‑5份，姜黄素：5‑100份，和任选的可接受的辅料：0‑350份。通过使用天然物质的成分来促进人体的免疫系统，并减少关节发炎和骨关节炎进展，从而达到预防和/或治疗骨关节炎的目的。
Description
技术领域
本发明属于药品或保健品技术领域，具体涉及一种组合物，特别涉及一种通过提升免疫力来预防和/或治疗骨关节炎的组合物及其应用。
背景技术
骨关节炎(OA)是关节的一种慢性退行性疾病，是全球最常见的疾病之一。由于人口老龄化，其患病率和严重性正在增加，但是治疗选择仍然主要限于止痛药和消炎药，它们只能缓解症状。在疾病的晚期，通常需要外科手术来部分恢复关节功能。尽管骨关节炎研究的重点最初集中在关节软骨上，但现在新发现将骨关节炎视为整个关节的疾病，骨关节炎导致关节发炎，关节软骨破裂和逐渐消失。
骨关节炎(OA)传统上被归类为非炎性关节炎。然而，随着人们对OA关节和滑膜内大量正在进行的免疫过程的认识，炎症性关节炎和变性关节炎之间的二分法变得越来越不清楚。滑膜炎定义为滑膜的炎症，是典型的炎症性关节炎的特征。OA是一种更为复杂的疾病，其炎症介质由软骨、骨骼和滑膜释放。由代谢综合征、先天免疫和发炎引起的低度炎症是支持OA炎症理论的最新观点。OA的进行性关节衰竭特征与关节损伤的相互作用，对感知损伤的免疫反应以及随后的慢性炎症状态密切相关，从而导致向临床OA表型的传播和发展。
到目前为止，尚无治疗方法可以逆转OA的损害。用于骨关节炎的药物主要为非甾体抗炎药，具有消炎和止痛作用，适合炎症性疼痛；但这类药物会导致恶心、呕吐等消化道不适，长期使用还会增加消化道出血的风险。其他物理疗法仅用于维持受关节炎影响的活动性。对于骨关节炎的预防和治疗尚缺乏有效的保健品或食物。通过使用天然药物成分来增强人体免疫力及加强抗炎能力，从源头上预防和减少骨关节炎的发生，可填补骨关节炎预防和治疗的空缺。
改性柑橘果胶(MCP)是富含柑橘类果皮的成分，被用作免疫支持、癌症、重金属毒性和纤维化疾病的治疗剂。MCP在炎症、纤维化和癌症进展中的作用机制是它可以作为细胞外半乳糖凝集素3(Galectin-3或Gal-3)的竞争性抑制剂。虾青素是一种类胡萝卜素色素，存在于鳟鱼，微藻，酵母和虾以及其他海洋生物中，可以清除体内自由基、延缓衰老、有益关节、增强免疫力、有益眼睛和大脑、增强耐力、抗衰老作用。而姜黄作为一种香料已有数百年历史,以其抗炎和抗氧化特性而闻名，并已被研究为天然抗某些癌症和阿尔茨海默氏病的疗法，姜黄素是姜黄的活性最高的化合物，因此具有潜在的抗炎健康益处。乳香，又称印度乳香，是从乳香锯缘青蟹树中提取的草药提取物，由乳香提取物制成的树脂已在亚洲和非洲民间医学中使用了多个世纪，可以治疗慢性炎症性疾病。
发明内容
针对上述存在的问题，本发明提供了一种组合物，通过使用天然物质的成分来促进人体的免疫系统，并减少关节发炎和OA进展，从而达到预防和/或治疗骨关节炎的目的。
根据本发明的一个方面，提供了一种组合物，其包含具有以下重量份的组分：
改性柑橘果胶(MCP)：5-150份，例如10-150份，
乳香(乳香酸)：5-100份，
虾青素：1-5份，
姜黄素：5-100份，和
任选的可接受的辅料：0-350份，例如30-350份。
根据本发明的一个实施方式，所述组合物以(10-50):(5-20):(1-3):(10-50):(0-70)的重量比包含改性柑橘果胶(MCP)、乳香(乳香酸)、虾青素、姜黄素和任选的可接受的辅料。
根据本发明的一个实施方式，所述组合物以(10-30):(5-20):(1-3):(5-20):(0-70)的重量比包含改性柑橘果胶(MCP)、乳香(乳香酸)、虾青素、姜黄素和任选的可接受的辅料。
根据本发明的一个实施方式，所述组合物以(10-25):(5-15):(1-2):(5-15):(30-50)的重量比包含改性柑橘果胶(MCP)、乳香(乳香酸)、虾青素、姜黄素和任选的可接受的辅料。
在根据本发明的组合物中，改性柑橘果胶(MCP)、虾青素具有免疫增强及免疫调节作用，姜黄、乳香具有抗炎作用，各组分之间具有协同作用，通过增强免疫、抑制炎症发生，从而改善和治疗关节炎。
本发明采用的姜黄素被称为“生物保护剂”，具有抗氧化功效，可以清除自由基并阻止自由基进一步生产。其具有抗炎功效，可抑制炎症因子，如肿瘤坏死因子TNF-α，白细胞介素(IL-1、IL-6、IL-8)和前列腺素PGE2等。曾有学者研究了姜黄对关节炎炎症抑制的功效，研究表明，姜黄素抑制中性粒细胞活化，抑制滑膜细胞增殖和血管新生；姜黄素在低浓度下强烈抑制胶原蛋白酶和基质降解酶的表达。它不会像常用的非甾体抗炎药(NSAIDs)，对胃肠产生副作用。
而虾青素作为一种营养补充剂，可以清除体内自由基、延缓衰老、有益关节、增强免疫力、有益眼睛和大脑、增强耐力、抗衰老。
柑橘果胶广泛存在于植物的初生细胞壁和中胞间层，是植物细胞壁的主要成分之一。目前国内外已有多项临床前研究表明在离体细胞水平或整体动物体内，对多种肿瘤具有抑制作用，包括乳腺癌、卵巢癌、前列腺癌、胃癌、结肠癌以及白血病等，可以作为细胞外半乳糖凝集素3(Gal-3)的竞争性抑制剂。MCP通过减少巨噬细胞活性，减少炎症和骨吸收。
乳香，又称印度乳香，是从乳香锯缘青蟹树中提取的草药提取物，由乳香提取物制成的树脂已在亚洲和非洲民间医学中使用了多个世纪，可以治疗慢性炎症性疾病。
本发明还提供了上述的组合物在制备用于预防和/或治疗骨关节炎的药物或保健品中的应用。
所述药物或保健品提高人体的免疫力、防止关节软骨退化、能使损伤关节软骨再生或直接治疗骨关节炎损伤或增强免疫，防止关节的骨赘生成。
本发明还提供了一种用于缓解骨关节炎疼痛的保健品，由本发明上述的组合物和保健品中可接受的辅料组成。
在本发明，合适的辅料可以选自交联羧甲纤维素钠、硬脂酸镁、滑石粉、蔗糖、共聚维酮、二氧化硅、羧甲纤维素钠、预胶化淀粉等中的一种或多种。
本发明的药物或保健品可以采用以上原料药，采用通常的工艺方法制成药剂，包括但不限于散剂、粉剂、片剂、胶囊剂、颗粒剂、丸剂或口服液等剂型。
本发明还提供了一种所述组合物的制备方法，该方法包括以下步骤：
(1)粉碎：将所述组合物的各组分研磨破碎，过80-100目筛滤；
(2)混合：将粉碎后的各组分按照配方的称量，混合搅拌约6-15分钟制成。
本发明具有如下优点或有益效果：
本发明的组合物为天然物质提取物或天然物质，具有较高的纯度，同时相对于单一组分的作用，联合各组分配伍使用，不仅能增强治疗效果，还能使各组分之间发挥协同作用，通过提高免疫力，对缓解关节疼痛、促进关节保健起到了显著的增效作用，同时增进了对骨骼生长和骨质代谢的作用。
附图说明
图1显示了本申请实验例中各试验组小鼠的股骨远端的定量小梁骨密度比较；
图2示出了实验例中各试验组小鼠矿化骨赘体积形成比较；
图3-1示出了实验例中各试验组总骨赘(软骨和矿物质)、OARSI评分和滑膜炎评分比较；
图3-2示出了小鼠关节切片用H&E染色后的代表性图像；
图4显示了实验例中各试验组小鼠软骨下小梁和矿化骨赘体积形成比较。
具体实施方式
下面通过具体实施方式来进一步说明本发明，以下实施例为本发明具体的实施方式，其旨在示例说明本发明的技术方案和效果，但本发明的范围并不受下述实施例的限制。
本发明实施例所采用的原料或试剂和实验动物均来源于市购产品，除特殊说明外，所采用的方法为本领域的常规方法。
姜黄素(批号：ST-04-001，厂家：广州顺彤医药化工有限公司)、改性柑橘果胶(批号：LM2017121212，厂家：河南如立生物科技有限公司)、乳香酸(批号：yky-00163，厂家：西安耀康源生物科技有限公司)、虾青素(批号：A090，厂家：陕西金润生物科技有限公司)、PBS溶液(磷酸盐缓冲生理盐水)(批号：B548117-0500，厂家：生工生物工程(上海)股份有限公司)、塞来昔布(批号：Z6862，厂家：辉瑞制药有限公司)、BALB/C裸鼠(购于广西医科大学动物中心)。
实施例1-5：
1.粉碎：根据下表1和2将各实施例各组合物的各组分研磨破碎，过80-100目筛滤；
2.混合：将各组分按照配方的组份及重量份称量，放置三维搅拌机中，混合搅拌约6-15分钟，制成各组粉剂。
表1：实施例1-5组合物的组分及重量份数
表2实施例1-5辅料的组分及重量份数
比较例1-2
采用改性柑橘果胶(MCP)单独组分作为比较例1，采用姜黄素单独组分作为比较例2。
实验例
将实施例1、实施例5以及比较例1和2的粉剂和塞来昔布，加入一定体积的PBS溶液，进行超声溶解，用PBS溶液进行定容，制成浓度为0.1mg/ml的各试验组溶液。
70只SD小鼠，20-30g雌雄各半，随机分为7组:正常组(假手术组，)、骨关节炎组、塞来昔布组、天然促免疫组(四种复方：高剂量组(实施例5)、低剂量组(实施例1))和比较对照组(比较例1和比较例2)。天然促免疫组(低剂量组、高剂量组)分别灌服相应药物溶液(试验组1和试验组2)，正常组和骨关节炎组灌服相应剂量的PBS溶液，塞来昔布组灌服相应剂量的塞来昔布，比较对照组分别灌服相应单组分药物溶液(试验组3和试验组4)。
表3：试验组设置及干预方案
上表3中的正常组是指对未经DMM切除的正常小鼠施用PBS溶液的假手术组。
本研究中使用的小鼠模型涉及膝关节内侧半月板(DMM)切除手术，使关节不稳定以诱发骨关节炎。该模型是最小侵入性且完全无菌的，因此很可能不涉及与手术模型相关的最小程度的疼痛和不适。DMM模型模仿临床半月板损伤，这是人类OA发生的已知诱发因素，并允许研究疾病过程中的结构和生物学变化。
内侧半月板去稳定手术模型DMM主要在内侧胫骨平台和股骨内侧髁的中央负重区域导致损伤。DMM模型中的病变从术后4周的轻度至中度OA发展到术后8周的中度至重度膝关节骨关节炎。
术后第1天口服各组干预成分或药物溶液治疗，持续8周。
小鼠在饲养后8周被处死，进行软骨下骨量和微结构的结构学检查。采用关节切片对骨性关节炎组进行Micro-CT组织学检查，按OARSI进行标准评分，包括测量关节软骨厚度、软骨侵蚀，定量测量矿化和非矿化骨赘的形成。通过Micro-CT进行软骨下骨结构测量。使用VivaCT 40(Scanco Medical，Bassersdorf Switzerland)扫描并分析了包括股骨远端和胫骨近端在内的右膝关节，各向同性标称体素尺寸为10μm，并且单能(70keV)X射线源。使用3D图像配准方案和sigma＝0.8，支撑＝1的高斯滤波器，评估了以膝盖关节为中心的整个膝盖的总长645mm，以获得总膝盖骨体积/组织体积(BV/TV)的比率。对于带骨赘或仅膝盖的全膝关节，阈值＝230。矿化的骨赘的体积是通过轮廓化包括骨赘的膝盖的总体积得出的，然后从仅勾勒膝盖关节的轮廓中减去骨骼的总体积。
天然促免疫治疗不会影响小鼠的总体健康状况和体重。高剂量组对骨关节炎的影响与低剂量组相似，此处仅报道低剂量组(实施例1)的疗效。
图1显示了本申请实验例中各试验组小鼠的股骨远端的定量小梁骨密度比较
与假手术组相比，骨关节炎(OA)组膝关节小梁骨丢失。所有单一疗法均无法挽救骨质流失，但四种组合可预防骨质流失。因此，单一疗法不能有效地预防骨质疏松症，而四种组合疗法则可以。*P＜0.05，与DMM-PBS生理盐水治疗组(骨关节炎组)比较。
图2示出了各试验组小鼠矿化骨赘体积形成比较
与假手术组相比，OA组(骨关节炎组)膝关节周围的矿化骨赘形成多60％(箭头)。塞来昔布治疗没有减少矿化骨赘形成(骨赘形成与OA组相似)。天然促免组减少矿化的骨赘形成。*P＜0.05，与DMM-生理盐水治疗组(骨关节炎组)比较。
图3示出了各试验组总骨赘(软骨和矿物质)、OARSI评分和滑膜炎评分比较
DMM模型中的联合组织学。免疫前联合用药和生理盐水治疗8周后，从DMM小鼠获得膝关节组织切片。关节切片用H&E染色，显示了小鼠关节的代表性图像(图3-2)。测量总骨赘(软骨和矿物质)，OARSI评分和滑膜炎评分(图3-1)。*P＜0.05，与DMM-生理盐水治疗组(骨关节炎组)比较。
图4显示了实验例中各试验组小鼠软骨下小梁和矿化骨赘体积形成比较
与假手术组相比，骨关节炎组的软骨下小梁骨数量减少，软骨下小梁骨连接密度降低，并且在股骨软骨内侧部位形成了骨赘(黑色椭圆形)。塞来昔布治疗没有改善软骨下骨微结构，减少矿化骨赘形成。复方天然促免疫组维持软骨下骨微结构，减少矿化的骨赘形成。*P＜0.05，与生理盐水治疗组(骨关节炎组)比较。
结论：与假手术组相比，DMM组在第8周表现出变性增加，股骨的软骨侵蚀扩展至关节表面的25％，胫骨平台的垂直裂隙扩展至小于关节表面的25％。DMM引起内侧(手术侧，箭头)关节软骨的缺失，也伴随着外侧半月板矿化增加(箭头)，外侧骨赘形成(箭头)和滑膜炎症增加。与DMM-生理盐水治疗组(骨关节炎组)相比，在不稳定的内侧半月板的天然促免疫组治疗组中，股骨和胫骨平台处的OARSI得分显着降低了约30％。天然促免疫组显著地减少软骨损伤，显著地减少骨赘形成和关节间隙变窄。
Claims (10)
1.一种组合物，其包含具有以下重量份的组分：
改性柑橘果胶：5-150份，
乳香：5-100份，
虾青素：1-5份，
姜黄素：5-100份，和
任选的可接受的辅料：0-350份。
2.根据权利要求1所述的组合物，其中，所述组合物包含改性柑橘果胶：10-150重量份。
3.根据权利要求1所述的组合物，其中，所述组合物以(10-50):(5-20):(1-3):(10-50):(0-70)的重量比包含改性柑橘果胶、乳香、虾青素、姜黄素和任选的可接受的辅料。
4.根据权利要求1所述的组合物，其中，所述组合物以(10-30):(5-20):(1-3):(5-20):(0-70)的重量比包含改性柑橘果胶、乳香、虾青素、姜黄素和任选的可接受的辅料。
5.根据权利要求1所述的组合物，其中，所述组合物以(10-25):(5-15):(1-2):(5-15):(30-50)的重量比包含改性柑橘果胶、乳香、虾青素、姜黄素和可接受的辅料。
6.根据权利要求1至5中任一项所述的组合物在制备用于预防和/或治疗骨关节炎的药物或保健品中的应用。
7.一种用于缓解骨关节炎疼痛的药物或保健品，其由权利要求1至5中任一项所述的组合物和药物或保健品中可接受的辅料组成。
8.根据权利要求7所述的药物或保健品，其中所述的辅料选自交联羧甲纤维素钠、硬脂酸镁、滑石粉、蔗糖、共聚维酮、二氧化硅、羧甲纤维素钠、预胶化淀粉中的一种或多种。
9.根据权利要求7所述的药物或保健品，其中，所述药物或保健品为散剂、粉剂、片剂、胶囊剂、颗粒剂、丸剂或口服液。
10.根据权利要求1至5中任一项所述的组合物的制备方法，该方法包括以下步骤：
(1)粉碎：将所述组合物的各组分研磨破碎，过80-100目筛滤；
(2)混合：将粉碎后的各组分按照配比称量，混合搅拌约6-15分钟制成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011101697.3A CN114366764A (zh) | 2020-10-15 | 2020-10-15 | 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011101697.3A CN114366764A (zh) | 2020-10-15 | 2020-10-15 | 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114366764A true CN114366764A (zh) | 2022-04-19 |
Family
ID=81138875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011101697.3A Pending CN114366764A (zh) | 2020-10-15 | 2020-10-15 | 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114366764A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060040000A1 (en) * | 2004-08-11 | 2006-02-23 | Gokaraju Ganga R | Dietary supplement formulation for controlling inflammation and cancer |
| US20080020998A1 (en) * | 2006-07-24 | 2008-01-24 | Muhammed Majeed | Sustained release compositions for the therapeutic management of pain, inflammation and inflammation-associated disorders and prophylactic/ therapeutic methods thereof |
| CN109480213A (zh) * | 2018-12-13 | 2019-03-19 | 北京康比特体育科技股份有限公司 | 一种具有关节保养及修护的运动营养品搭配组合物 |
| CN110051822A (zh) * | 2019-06-12 | 2019-07-26 | 汤臣倍健股份有限公司 | 一种缓解关节疼痛的组合物及其保健品、应用 |
| KR102018221B1 (ko) * | 2018-03-08 | 2019-09-04 | 케일럽 멀티랩(주) | 보스웰리아 추출물, 포도씨 추출물, 강황 추출물, 녹차 추출물, 생강 추출물 및 백미 추출물을 유효성분으로 함유하는 관절염의 예방, 개선 또는 치료용 조성물 |
| CN110771741A (zh) * | 2019-11-11 | 2020-02-11 | 深圳市红瑞生物科技有限公司 | 组合物、制备方法及其在制备关节养护药品、保健品及食品中的应用 |
-
2020
- 2020-10-15 CN CN202011101697.3A patent/CN114366764A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060040000A1 (en) * | 2004-08-11 | 2006-02-23 | Gokaraju Ganga R | Dietary supplement formulation for controlling inflammation and cancer |
| US20080020998A1 (en) * | 2006-07-24 | 2008-01-24 | Muhammed Majeed | Sustained release compositions for the therapeutic management of pain, inflammation and inflammation-associated disorders and prophylactic/ therapeutic methods thereof |
| KR102018221B1 (ko) * | 2018-03-08 | 2019-09-04 | 케일럽 멀티랩(주) | 보스웰리아 추출물, 포도씨 추출물, 강황 추출물, 녹차 추출물, 생강 추출물 및 백미 추출물을 유효성분으로 함유하는 관절염의 예방, 개선 또는 치료용 조성물 |
| CN109480213A (zh) * | 2018-12-13 | 2019-03-19 | 北京康比特体育科技股份有限公司 | 一种具有关节保养及修护的运动营养品搭配组合物 |
| CN110051822A (zh) * | 2019-06-12 | 2019-07-26 | 汤臣倍健股份有限公司 | 一种缓解关节疼痛的组合物及其保健品、应用 |
| CN110771741A (zh) * | 2019-11-11 | 2020-02-11 | 深圳市红瑞生物科技有限公司 | 组合物、制备方法及其在制备关节养护药品、保健品及食品中的应用 |
Non-Patent Citations (4)
| Title |
|---|
| ADRIANA F;等: "乳香-姜黄素制剂治疗膝骨关节炎的临床评价", 国外医药.植物药分册, vol. 20, no. 01, pages 2 - 3 * |
| URI ARAD;等: "Galectin-3 is a sensor-regulator of toll-like receptor pathways in synovial fibroblasts", CYTOKINE, vol. 73, no. 01 * |
| 裴凌鹏;等: "虾青素对兔骨性关节炎软骨细胞增殖与凋亡影响的研究", 时珍国医国药, vol. 23, no. 05, pages 1062 - 1064 * |
| 裴凌鹏;等: "虾青素胶囊治疗膝关节骨性关节炎疗效观察", 中国临床新医学, vol. 05, no. 06 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2730286B1 (en) | Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints | |
| EP2068891B1 (en) | Composition comprising crustacean gastrolith components, calcium carbonate and its use | |
| US10653655B2 (en) | Composition for preventing or improving peripheral neuropathy | |
| TWI382841B (zh) | 用於抑制發炎之醫藥組合物 | |
| CN111467481A (zh) | 一种改善和/或预防骨关节炎的组合物及其应用 | |
| JP6218732B2 (ja) | 変形性関節症予防又は治療用組成物 | |
| CN114366764A (zh) | 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物 | |
| WO2019134534A1 (zh) | 一种e-10-羟基-2-癸烯酸在制备防治骨质疏松症的药品或保健品中的应用 | |
| KR20230145464A (ko) | 고지혈증을 치료하는 약물 조성물 및 그 제조 방법 | |
| CN114366807B (zh) | 一种用于预防和/或治疗骨关节炎的组合物 | |
| KR20120045122A (ko) | 관절염을 포함한 골 질환 예방 및 치료용 조성물 | |
| KR101120499B1 (ko) | 골 질환의 예방 및 치료용 조성물 | |
| JP6547183B2 (ja) | トリテルペンを有効成分として含有する変形性関節症の予防又は治療の為の組成物 | |
| KR20200043783A (ko) | 감잎 유래 다당 분획물을 함유하는 골 관련 질환의 개선, 예방 또는 치료용 조성물 | |
| JP6280076B2 (ja) | オシダ科植物含有組成物 | |
| KR20140113199A (ko) | 초과 추출물을 유효성분으로 포함하는 골 질환의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물 | |
| KR20190101632A (ko) | 한약재를 포함하는 항염용 조성물 | |
| KR101890858B1 (ko) | 알파-이소-큐베베놀 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 류마티스 관절염 예방, 개선 또는 치료용 조성물 | |
| AU5778801A (en) | Improvements in effervescent tablet manufacture | |
| JP2023032210A (ja) | 関節滑膜の抗炎症剤 | |
| CN113230381A (zh) | 一种增加骨密度的配方 | |
| US20130079299A1 (en) | Arthritis Therapeutic Agent | |
| JP2023129314A (ja) | コレステロール吸収阻害剤 | |
| KR20110121088A (ko) | 치료 후 손상된 세포조직의 재생과 성장 및 체내 면역력을 증가시켜주는 2차 감염 방지용 면역강화 조성물 | |
| KR20120045124A (ko) | 에타크릭산을 유효성분으로 포함하는 골 질환 예방 및 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240313 Address after: Room 509, Building 2, Dezhong Plaza, No.1 Exhibition East Road, Torch Development Zone, Zhongshan City, Guangdong Province, 528437 Applicant after: Zhongshan Laibo Ruichen biomedical Co.,Ltd. Country or region after: China Address before: 530021 805, Guangxi talent building, No. 33, Jinzhou Road, Qingxiu District, Nanning City, Guangxi Zhuang Autonomous Region Applicant before: Laibo Ruichen Biomedical Technology Co.,Ltd. Country or region before: China |